Jennifer Giottonini Cayer has over 25 years of biotech, pharmaceutical and medical device experience. She has held executive management positions at both venture-backed and publicly traded companies. Cayer has executed multiple acquisitions and alliances with pharmaceutical and biotech companies worth over $5 billion. She successfully co-founded a venture-backed biotech company now trading on the NASDAQ.
Most recently, Cayer co-founded two venture-backed biotech companies including Travus Therapeutics and Chromis Therapuetics. Prior to the creation of those companies, Cayer was the chief operating officer of Rempex Pharmaceuticals, acquired by The Medicines Company just two years after the company was founded. While at Rempex, she acquired a commercial stage therapeutic and facilitated the sale of the company. She joined Rempex from Conatus Pharmaceuticals, a company she co-founded and served as the senior vice president, corporate development. Ms. Cayer led the negotiations for the acquisition of multiple drug candidates from pharmaceutical companies including the acquisition of the Idun subsidiary of Pfizer.
Prior to Conatus, she was the head of corporate development for Idun Pharmaceuticals, Inc. Ms. Cayer played a key role in the negotiations leading to the sale of Idun to Pfizer.
Prior to Idun, Ms. Cayer spent five years at Isis/Ionis Pharmaceuticals, where she advanced to vice president, business development. She has held various technical, marketing, and operational roles at Gensia and Puritan Bennett (Tyco).
Ms. Cayer graduated from the University of California, San Diego with a B.S. in Bioengineering.
She has previously served as a member of the board of directors for Athena, and Travus Therapeutics and currently is a board member with Chromis Therapeutics and founding co-chair for the advisory committee for Biocom’s global partnering conference.
The hot topic of getting more qualified women on corporate boards continues unabated. Recent statistics show how companies with women prominently serving in such capacities experience higher-than-average financial performance. A major... Read more »